We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
76
Crinetics Pharmaceuticals
CRNX
$8.99B
$5.57M 0.02%
317,857
+142,857
+82% +$2.44M
CBAY
77
DELISTED
Cymabay Therapeutics
CBAY
$5.32M 0.02%
+1,522,792
New +$4.39M
CHMA
78
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.09M 0.02%
+946,701
New +$5.21M
IFRX icon
79
InflaRx
IFRX
$309M
$4.86M 0.02%
1,058,555
-719,860
-40% -$4.67M
ABEO icon
80
Abeona Therapeutics
ABEO
$348M
$4.64M 0.02%
63,627
– –
EVFM
81
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.03M 0.02%
95,000
+53,580
+129% +$3.61M
CNST
82
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.01M 0.02%
133,333
– –
OVID icon
83
Ovid Therapeutics
OVID
$547M
$3.38M 0.01%
458,253
+388,782
+560% +$1.82M
KZR
84
DELISTED
Kezar Life Sciences
KZR
$3.11M 0.01%
+60,000
New +$3.03M
VKTX icon
85
Viking Therapeutics
VKTX
$3.95B
$3.06M 0.01%
425,000
– –
GMDA
86
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.05M 0.01%
+666,666
New +$3.06M
DRNA
87
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.03M 0.01%
119,335
+37,400
+46% +$806K
RCUS icon
88
Arcus Biosciences
RCUS
$3.86B
$3.01M 0.01%
121,534
– –
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.97M 0.01%
47,000
– –
ARAV
90
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.84M 0.01%
244,055
-242,278
-50% -$2.87M
NTLA icon
91
Intellia Therapeutics
NTLA
$1.8B
$2.7M 0.01%
128,538
– –
LKFT
92
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$2.58M 0.01%
13,072
– –
XLRN
93
DELISTED
Acceleron Pharma
XLRN
$2.57M 0.01%
27,000
– –
DNLI icon
94
Denali Therapeutics
DNLI
$3.98B
$2.54M 0.01%
104,900
– –
NGM
95
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.46M 0.01%
124,400
-125,600
-50% -$2.4M
ORTX
96
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.43M 0.01%
40,570
– –
APLT
97
DELISTED
Applied Therapeutics
APLT
$2.38M 0.01%
65,934
– –
IMTX icon
98
Immatics
IMTX
$1.22B
$2.36M 0.01%
150,000
– –
CPRX
99
DELISTED
Catalyst Pharmaceutical
CPRX
$2.31M 0.01%
500,000
-560,714
-53% -$2.52M
MTEM
100
DELISTED
Molecular Templates, Inc.
MTEM
$2.18M 0.01%
10,548
-5,313
-33% -$1.23M
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2020 Portfolio in Review

As of Q2 2020, Julian Baker held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Julian Baker added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Julian Baker's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Julian Baker fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Julian Baker's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Julian Baker opened 14 new positions and closed 10 in Q2 2020.
  • Julian Baker's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.